NeurAxis, Inc. (NYSE: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025.
Revenues increased 27% year over year to $968 thousand in 4Q25.
Its operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth.
Cash balance was $5.0 million as of December 31, 2025.
Revenues for FY2025 increased 33% year over year to $3.6 million.
Operating loss increased 9% year over year, primarily due to a one-time non-recurring legal settlement.
“Excluding the legal settlement,” according to this morning’s news release, “the Company’s operating loss was flat year over year despite its investment in selling expenses that were offset by higher gross profit from increased sales volume.”
Moreover, the company was awarded a Veterans Affairs Federal Supply Schedule (FSS) contract, officially designating NeurAxis as a federal contractor and creates a clear commercial pathway into the Veterans Affairs health system, which serves nearly seven million patients annually.
Awarded the first-ever FDA clearance for the treatment of abdominal pain in functional dyspepsia (FD), with associated nausea symptoms, in patients eight years of age and older, expanding the total addressable market for IB-Stim.
NRXS shares dropped 64 cents, or 9.2%, to $6.35.
